Spots Global Cancer Trial Database for high grade
Every month we try and update this database with for high grade cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma | NCT00282087 | Leiomyosarcoma Uterine Neoplas... | gemcitabine, do... | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| Bevacizumab/Doxorubicin/Radiation for Sarcoma | NCT01746238 | Sarcoma | Bevacizumab Doxorubicin Radiation Thera... | 18 Years - | Massachusetts General Hospital | |
| Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | NCT01623349 | Ovarian Cancer Breast Cancer | BKM120 and Olap... BYL719 and Olap... | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma | NCT00660283 | Glioma | Temozolomide | 18 Years - 75 Years | Kentuckiana Cancer Institute | |
| Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer | NCT02143804 | Bladder Cancer High Grade Non Muscle Inva... | oncolytic adeno... | 18 Years - | CG Oncology, Inc. | |
| FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | NCT03042780 | Gastro-enteropa... Pancreatic Canc... Neuroendocrine ... Islet Cell Carc... | FOLFIRINOX Granulocyte col... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Pembrolizumab in Patients With Neuroendocrine Tumors | NCT02939651 | Neuroendocrine ... | Pembrolizumab | 18 Years - | Fox Chase Cancer Center | |
| Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma | NCT00282087 | Leiomyosarcoma Uterine Neoplas... | gemcitabine, do... | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors | NCT00935545 | Tumors, Central... | Montanide | - 21 Years | NYU Langone Health | |
| Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer | NCT02143804 | Bladder Cancer High Grade Non Muscle Inva... | oncolytic adeno... | 18 Years - | CG Oncology, Inc. | |
| A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract | NCT05868265 | Urothelial Carc... | Enfortumab Vedo... Radical surgery | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | NCT01623349 | Ovarian Cancer Breast Cancer | BKM120 and Olap... BYL719 and Olap... | 18 Years - | Dana-Farber Cancer Institute | |
| Bevacizumab/Doxorubicin/Radiation for Sarcoma | NCT01746238 | Sarcoma | Bevacizumab Doxorubicin Radiation Thera... | 18 Years - | Massachusetts General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
